Clinical Trial
Published on 17 Jan 2023
SDI-118, a novel procognitive SV2A modulator: First-in-human randomized controlled trial including PET/fMRI assessment of target engagement
in Translational Pharmacology
Frontiers in Pharmacology
doi 10.3389/fphar.2022.1066447
- 5,248 views
- 9 citations



